To evaluate the cost-effectiveness of solifenacin 5 mg/day versus other oral antimuscarinic agents used for overactive bladder (OAB) from a UK National Health Service (NHS) perspective. In a Markov model, hypothetical patients received solifenacin 5 mg/day or a comparator antimuscarinic, after which they could switch to an alternative antimuscarinic. The model estimated incremental cost-effectiveness ratios (ICER), expressed as cost per quality-adjusted life year (QALY) over a 5-year period. Solifenacin 5 mg/day was the dominant treatment strategy (i.e., less costly and more effective) versus tolterodine extended-release (ER) 4 mg/day, fesoterodine 4 and 8 mg/day, oxybutynin ER 10 mg/day and solifenacin 10 mg/day, and was cost-effective (i.e., ICERs below the £30,000 per QALY threshold generally applied in the NHS) versus oxybutynin immediate release (IR) 10 mg/day, tolterodine IR 4 mg/day and trospium chloride 60 mg/day. The probability of solifenacin 5 mg/day being dominant/cost-effective at a willingness-to-pay threshold of £30,000 per QALY was 57-98%. Solifenacin 5 mg/day appears to be a cost-effective strategy for the treatment of OAB over a 5-year timeframe compared with other oral antimuscarinic agents in the UK. These findings are important for decision-makers considering the economic implications of selecting treatments for OAB.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907635 | PMC |
| http://dx.doi.org/10.1080/20016689.2018.1438721 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction.
Prostate Cancer Prostatic Dis
June 2024
Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Background: Low-intensity shockwave therapy (Li-SWT) can improve bladder function through enhancement of angiogenesis and nerve regeneration and suppression of inflammation and overactivity. In this trial, we aimed to evaluate the efficacy of Li-SWT on persistent storage symptoms after transurethral surgery (TUS) for benign prostatic obstruction (BPO).
Methods: Between July 2020 and July 2022, 137 patients with persistent storage symptoms; urgency episodes/24 h ≥ 1 and daytime frequency ≥8, for at least three months after TUS for BPO were randomly allocated to Li-SWT versus sham versus solifenacin 10 mg/day in 3:1:1 ratio.
A randomized controlled trial study on effectiveness between tadalafil versus combination mirabegron and solifenacin on treatment of ureteral stent-related symptoms.
Pan Afr Med J
November 2023
Division of Urology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
Introduction: ureteral stents have common complications like ureteral stent-related symptoms (SRSs). This study investigated the effectiveness of tadalafil compared to mirabegron and solifenacin combination therapy in patients with ureteral SRSs after double-J (DJ) stent insertion.
Methods: this double-blind, randomized clinical trial used consecutive random sampling in participants with SRSs after double-J stent insertion.
Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms-A randomized controlled trial.
Low Urin Tract Symptoms
July 2023
Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
Article Synopsis
- This study assesses how effective beta-3 agonists (mirabegron) and antimuscarinic agents (solifenacin) are for treating overactive bladder in patients with Sjogren syndrome.
- A total of 41 Sjogren's patients were assigned to receive either mirabegron or solifenacin, with improvements in bladder symptoms observed in both groups after 12 weeks, although solifenacin had more patients switch due to side effects.
- Ultimately, mirabegron was found to be just as effective as solifenacin but caused fewer adverse events, making it a preferable option for managing overactive bladder in these patients.
Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis.
Front Neurosci
February 2023
Department of Neurology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Introduction: Overactive bladder (OAB) is one of the most common complications in patients with multiple sclerosis (MS). Choosing the effective treatment is very important in improving their quality of life (QOL). Therefore, the aim of this study was to compare solifenacin (SS) and posterior tibial nerve stimulation (PTNS) treatment effects in the MS Patients with OAB.
View Article and Find Full Text PDFEfficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients.
Asian J Urol
January 2022
Department of Public Health, Pacific State Medical University, Vladivostok, Primorsky region, Russian Federation.
Objective: To evaluate the efficacy and safety of simultaneous administration of dutasteride, tadalafil and solifenacin in the treatment of benign prostatic hyperplasia (BPH) with overactive bladder symptoms and lower urinary tract obstruction in previously unsuccessfully treated men.
Methods: Patients in Group A (=97) received dutasteride 0.5 mg/day, tadalafil 2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!